Neolys Diagnostics
- Company typePrivate
- Founded2026
- HeadquartersLyon, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
Neolys Diagnostics firmographics
Firmographics- Name
- Neolys Diagnostics
- Legal name
- Gambloria
- Website
- https://neolysdiagnostics.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where Neolys Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Markets served
Neolys Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- House Edge (Game Wagers): Primary revenue from the mathematical house edge built into casino games. Players wager on games with RTP rates ranging from 92% to 98%, with the casino retaining the difference across all wagers placed.
- Bonus and Promotion Costs: Revenue partially offset by promotional spending including welcome bonuses (100% match up to €500 + 100 free spins), reload offers, cashback, and free spins. These are marketing costs that drive player acquisition and retention.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One-time | Welcome Bonus: 100% match up to €500 + 100 free spins for new accounts |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Neolys Diagnostics product offering
Product offeringCore offering
Neolys Diagnostics develops solutions that enable clinicians to adapt radiotherapy treatment to the individual radiosensitivity profile of each patient. The offering is positioned within precision medicine, supporting personalized cancer treatment planning based on patient-specific radiation response.
Differentiator
Problem solved
Functional benefit
Products and services
- Radiosensitivity-guided radiotherapy personalization solution
Quantifiable outcome
- RTP (Return to Player) rates ranging from 92% to 98% depending on game selected
- +1 more outcomes
Companies that use Neolys Diagnostics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Neolys Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Neolys Diagnostics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Pragmatic PlaycoreMajor game provider supplying slots, live casino, and rapid games to the Gambloria platform. Known for frequent bonus features, solid mobile interfaces, and broad game catalog.
- EvolutioncoreLeading live casino provider delivering live dealer tables and game show formats. Supplies roulette, blackjack, baccarat, and game show titles with professional streaming.
- NetEntcoreSlot game studio known for polished design, popular mechanics, and per-game RTP disclosure. Provides classic and video slots.
- Play'n GOcoreMobile-focused slot provider with extensive theme variety and varied volatility levels. Supplies video slots and mobile-optimized games.
- Relax GamingcoreInnovative provider supplying slots, jackpots, and modern game formats with dynamic pacing and contemporary mechanics.
- MicrogamingcoreEstablished provider supplying slots and progressive jackpot games including Mega Moolah and other jackpot titles.
Scale indicators3 records
Recent moves3 records
Expansion highlights2 records
Neolys Diagnostics competitors and assessment
Company assessmentDirect peers
- Exact Sciences: Acquired Genomic Health (Oncotype DX) whose DCIS and radiotherapy-decision-support tests directly use molecular predictors to guide radiation therapy decisions — the same conceptual niche Neolys targets. Closest publicly-traded comp.
- Caris Life Sciences: Provides comprehensive molecular profiling used by oncologists to select and tailor therapy, including radiation planning. Sells tumor profiling services to clinicians and competes for the same hospital formulary slot as a radiosensitivity assay.
Broad incumbents
- Myriad Genetics: Established companion diagnostics and oncology testing company (BRACAnalysis, myChoice, Prolaris). Operates in the same oncology molecular-diagnostics category, with established reimbursement and clinical-integration muscle that Neolys would need to match.
- Foundation Medicine: Roche-owned comprehensive genomic profiling provider for solid tumors. Sets the standard for therapy-selection molecular workups; any radiosensitivity assay must position relative to (or integrate with) FoundationOne CDx.
- Guardant Health: Liquid-biopsy-based oncology testing company whose Guardant360 CDx is used to guide treatment selection. Represents an adjacent technology modality (ctDNA vs. tissue-based radiosensitivity) competing for the same oncology precision-medicine budget.
- Veracyte: Genomic diagnostics company with oncology-focused tests (Decipher Prostate, Afirma) including radiation-decision-support products. Closely comparable business model of selling molecular tests to inform cancer treatment decisions.
- NeoGenomics Laboratories: Specialized oncology reference lab offering a broad menu of molecular and cytogenetic tests used by oncologists, including profiling that influences radiation planning. Competes for hospital lab partnerships.
Emerging players
- NanoString Technologies: Gene-expression profiling (nCounter, GeoMx) used in oncology research and translational biomarker development. Comparable technology approach (tissue-based expression assays) for radiation-response biomarker work.
- CureMatch: Decision-support platform that combines molecular profiling with oncology treatment matching (including drug/radiation combinations). Represents the clinical-decision-support layer that would integrate or compete with a radiosensitivity test.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Customer concentration
Neolys Diagnostics social profiles
Digital presenceNeolys Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neolys Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Neolys Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neolys Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neolys Diagnostics
What does Neolys Diagnostics do?
Neolys Diagnostics develops solutions that enable clinicians to adapt radiotherapy treatment to the individual radiosensitivity profile of each patient. The offering is positioned within precision medicine, supporting personalized cancer treatment planning based on patient-specific radiation response.
Is Neolys Diagnostics a public or private company?
Neolys Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Neolys Diagnostics founded?
Neolys Diagnostics was founded in 2026. It employs 1 to 10 people.
Where is Neolys Diagnostics based?
Neolys Diagnostics is headquartered in Lyon, France, in the Europe region.
How does Neolys Diagnostics make money?
Two revenue lines are on record. House Edge (Game Wagers) is the primary driver. The others are bonus and Promotion Costs.
Who are Neolys Diagnostics's main competitors?
Direct peers on record are Exact Sciences and Caris Life Sciences. Broad incumbents are Myriad Genetics, Foundation Medicine, Guardant Health, Veracyte and NeoGenomics Laboratories. Emerging players are NanoString Technologies and CureMatch.
Does Neolys Diagnostics have an API?
No public API is recorded for Neolys Diagnostics.